Tiziana Life Sciences Ltd

NASDAQ:TLSA

Biotechnology

Healthcare
$0.81 +2.78%

+$0.03 today

Market cap
$103.50M
Beta
0.42
P/E (TTM)
-4.0
EPS (TTM)
-$0.19
52W Low $1.04High $2.60

Volume 1.28M

Average 0.21M

TLSA Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Tiziana Life Sciences LtdNASDAQ: TLSA

Accounts Receivables · Q4 FY2025 · quarter ended Dec 2025

Accounts receivables turns positive

Q4 FY2025 accounts receivables was $577K, compared with -$541.78K a year earlier. Over 3 fiscal years it compounded at +75.9% a year.

Context

  • Accounts receivables grew in size in 1 of the last 3 fiscal years.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
$577K— QoQ
Last fiscal yearDec 2025
-$692K-37.7% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+206.5%——
1 year-37.7%——
3-year CAGR+75.9%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
(692K) USD
Year-over-year change
+37.7%

Accounts Receivables vs competitors

How TLSA compares with its peers on the latest reported figures

  • TLSA's FY2025 accounts receivables of $692K is the 2nd largest of the 9 companies compared; the peer median is $0.
  • Its year-over-year change of -37.7% is the 3rd highest of 6, against a peer median of -63.8%.
  • Over three fiscal years its annual growth of +75.9% compares with a peer median of -30.2%.
TLSA Competitors Peer median
Accounts Receivables for TLSA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
WHWKWhitehawk Therapeutics IncLTM Dec 2025$1M +141.0%-18.7%14.0%
TLSATiziana Life Sciences LtdFY2025$692K -37.7%+75.9%—
EXOZeXoZymes, Inc.LTM Mar 2026$187.09K -63.8%——
MGNXMacroGenics, Inc.LTM Mar 2026$117K +103.5%-41.7%0.1%
OKYOOKYO Pharma LimitedFY2025$90.4K -120.5%——
IMMXImmix Biopharma, Inc.LTM Mar 2026$55.2K -97.2%——
ZNTLZentalis Pharmaceuticals, Inc.LTM Mar 2026$0 ———
COYACoya Therapeutics, Inc.LTM Mar 2026$0 ——0.0%
PLRXPliant Therapeutics, Inc.LTM Mar 2026$0 ———
Peer median (excluding TLSA) $0-63.8%-30.2%0.1%

Competitors are the stored peer set for TLSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(17.36M)(12.55M)(14M)(9.48M)(18.43M)
Depreciation & Amortization104.52K41.57K75.97K99.09K234K
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital(573.01K)(948.89K)(1.25M)(441.1K)3.06M
Accounts Receivables317.27K(127.17K)(1.14M)(1.11M)(692K)
Inventory00000
Accounts Payables00000
Other Working Capital(890.27K)(821.72K)(109.21K)670.44K3.75M
Other Non-Cash Items1.7M(2.53M)2.75M8.6M2.29M
Operating Cash Flow(16.13M)(15.99M)(12.42M)(1.22M)(12.85M)
Capital Expenditures(16.31K)00(15.18K)(21K)
Acquisitions (Net)00000
Purchases of Investments0(2.18M)(791.35K)(52K)0
Sales of Investments00000
Other Investing Activities112.67K(1.08M)(200.21K)10.45K3.06M
Investing Cash Flow96.37K(3.26M)(991.57K)(56.74K)3.04M
Debt Repayment000(141K)0
Common Stock Issued95.62K0125.83K3.71M10.2M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(112.67K)(44.84K)(94.17K)28.33K(196K)
Financing Cash Flow(17.05K)(44.84K)31.65K3.6M10.01M
Effect of Forex Changes(1.53M)(324.45K)(22.16K)(293.27K)84K
Net Change in Cash(17.59M)(19.62M)(13.4M)2.03M286K
Free Cash Flow(16.15M)(15.99M)(12.42M)(1.23M)(12.87M)

Tiziana Life Sciences Ltd

NASDAQ:TLSA

Intrinsic Alpha fair value

Locked

Current Price

$0.81

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.